What should I ask at a vitiligo appointment?
Prepare exact questions about diagnosis, change, goals, options, follow-up and what matters in your life.
Last updated
What should I clarify about the diagnosis?
Ask what findings support the diagnosis and what remains uncertain. Bring a short history of when you first noticed change, where it appeared, and what has changed since. Evidence Evidence
What the sources support
Vitiligo is diagnosed clinically, sometimes with additional examination or selected tests. A conversation can distinguish what your clinician knows now from what still needs follow-up.
What remains individual or uncertain
A checklist or photograph cannot confirm a diagnosis or predict what will happen next.
Questions for your clinician
- What findings support vitiligo in my case? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Is anything about the diagnosis still uncertain? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What changes should prompt me to contact you? Saving keeps this on your device and needs JavaScript, which is off in this browser.
How should we discuss goals and options?
Name the outcome you care about and the burdens you can realistically take on. Ask about all reasonable paths, including observation or no active treatment for now. Evidence Evidence
What the sources support
Guidelines frame goals, disease activity, extent, prior care and personal priorities as part of shared decision-making.
What remains individual or uncertain
General information cannot tell you which option will help, what response you will have, or what your plan should be.
Questions for your clinician
- What are the reasonable options for my goals? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What are the main burdens and uncertainties of each option? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Is observation or no active treatment reasonable for me now? Saving keeps this on your device and needs JavaScript, which is off in this browser.
What follow-up plan do I need?
Leave knowing what to notice, what to record, and who to contact. Ask how your team will judge whether the plan is helping and what would lead to a review. Evidence
What the sources support
Clinical assessment can include change over time, photographs used within a care plan, treatment burden and quality-of-life concerns.
What remains individual or uncertain
The right follow-up approach depends on your situation and care setting; this page does not set a schedule.
Questions for your clinician
- What should I record between visits? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- How will we decide whether the plan is helping? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Who should I contact if I have a concern? Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports current US patient-language context that lighter patches have multiple causes, dermatologists diagnose vitiligo from history and examination, treatment is optional and several broad management paths exist.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish drug efficacy or comparative superiority.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.